Serum Ferritin Levels and Metabolic Dysfunction Associated Steatotic Liver Disease
Launched by THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY · May 28, 2024
Trial Information
Current as of February 19, 2025
Completed
Keywords
ClinConnect Summary
The diagnosis of MASLD was based on MRI. The diet scheme was formulated based on the results of body composition analysis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age between 18 and 80 years outpatients
- Exclusion Criteria:
- • previous diagnosis of diabetes acute and chronic complications acute and chronic inflammation long-term history of heavy alcohol consumption
Trial Officials
Ping Jin
Study Chair
The Third Xiangya Hospital of Central South University
About The Third Xiangya Hospital Of Central South University
The Third Xiangya Hospital of Central South University is a leading academic medical institution in China, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital focuses on a wide range of medical disciplines, emphasizing patient-centered approaches and evidence-based practices. With a commitment to improving treatment outcomes and enhancing patient care, the hospital collaborates with a diverse network of researchers and healthcare professionals, aiming to contribute significantly to the global medical community through rigorous scientific inquiry and high-quality clinical studies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Changsha, Hunan, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0